The extracellular signal-regulated kinase (ERK) signaling pathway is strongly activated in response to TCR stimulation in normal T cells. However, the extent to which activation of the ERK pathway is necessary for TCR-stimulated cytokine production is not clear. We have addressed this question by use of two separate methods to interfere with TCR activation of the ERK cascade. The first approach utilized transient expression of a catalytically inactive form of mitogen-activated/ERK 1 (CI-MEK1), while the second involved using the MEK1-and MEK2-specific inhibitor PD98059 to block ERK activation by the TCR. In order to assess the requirement for ERK activation in T cell cytokine production, we have measured the effect of ERK inhibition upon the production of six cytokines, IL-3, IL-4, IL-5, IL-10, granulocyte macrophage colony stimulating factor (GM-CSF) and IFN-γ, by newly activated normal mouse T cells in response to TCR stimulation. The results of experiments using both methods to block ERK activation have revealed a requirement for intact ERK signaling for the full elicitation of TCR-stimulated cytokine production. Dose-response analyses using the MEK inhibitor PD98059 showed that the TCR-stimulated production of all cytokines measured was affected by this treatment. However, the production of IL-3 and IL-4 was only partially dependent upon ERK activation, whereas IL-5, IL-10, IFN-γ and GM-CSF production was severely affected by diminished ERK activation. We conclude that the ERK pathway is differentially involved in the activation of different cytokine genes in normal T cells.
Introduction
T cells produce at least 15 different cytokines in response to stimulation of the TCR either by antigen-MHC complexes or by anti-TCR antibodies (reviewed in 1). An immediate consequence of TCR engagement is the activation of the protein tyrosine kinases pp60 fyn and ZAP-70, which in turn phosphorylate substrate proteins that regulate a number of downstream signaling cascades (reviewed in 2). Determining which signaling cascades are coupled to cytokine gene expression has been the focus of much recent attention. One of the best characterized pathways required for induction of cytokine gene expression is the calcium-dependent and cyclosporin A-sensitive pathway which regulates members of the nuclear factor of activated T cells (NF-AT) transcription factor family (reviewed in 3). A crucial component of this stress-activated protein kinases (JNK/SAPK) (6) (7) (8) (9) . The Rac-1/ JNK pathway acts primarily through induction of the AP-1 transcription factor (6) , which cooperatively interacts with NF-AT family members at a composite binding site located within the regulatory elements of many cytokine genes (reviewed in 3). However, these p21 ras -dependent pathways have only been well documented in the case of the IL-2 promoter in transformed T cell lines and much less is known about the regulation of other cytokines, particularly in normal T cells.
We have previously reported the results of experiments aimed at determining how p21 ras -dependent signaling via the MEK/ERK pathway affects the expression of several T cellderived cytokines. In these experiments, where we measured endogenous cytokine production rather than reporter gene activity, we have shown synergy between MEK/ERK activation and calcium-dependent signaling in eliciting cytokine production in normal T cells (10) . An important feature of our study was that MEK/ERK activation differentially affected the production of each cytokine measured, with a hierarchy of responsiveness as follows: IL-3 Ͼ granulocyte macrophage colony stimulating factor (GM-CSF) Ͼ IFN-γ ϾϾ IL-4 (10) . A consistent and important conclusion drawn from our study (10) and others (6, 11) was that, although capable of acting synergistically with other signaling pathways to elicit cytokine production, activation of the ERK pathway alone is insufficient to activate cytokine production. The question remained whether ERK activation is necessary for full TCR-stimulated cytokine production and whether the production of particular cytokines is differentially sensitive to inhibition of TCR-stimulated ERK activation.
The present study has addressed these questions using two separate approaches to blocking ERK activation by the TCR. The first involved expression of a catalytically-inactive version of MEK1 [CI-MEK1, created by conversion of Lys97 to Ala (12) ], and the second utilized the agent PD98059 as a specific inhibitor of both MEK1 and MEK2 (13, 14) . We demonstrate using both approaches that intact MEK/ERKdependent signaling is necessary for full TCR-stimulated production of the four cytokines we had previously analysed, IL-3, IL-4, IFN-γ and GM-CSF, as well as the two additional cytokines, IL-5 and IL-10. Production of IL-3 and IL-4 was relatively insensitive to ERK inhibition compared to the other cytokines measured, whereas IL-5, IL-10, GM-CSF and IFN-γ production was markedly reduced by ERK inhibition.
Methods
Antibodies, expression vectors and cDNA constructs Anti-c-myc mAb (9E10), purified polyclonal ERK1-and ERK2-specific antibodies, anti-hCD25 mAb, FITC-labeled goat antirat Ig antibodies, anti-LFA-1 mAb I21/7.7 and the anti-CD3 mAb 145-2C11 were all used as previously described (10) . Anti-JNK2-specific antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The human hCD25 cDNA, the N-terminally c-myc epitope-tagged ERK2 and the N-terminally influenza hemagglutinin epitope-tagged CI-MEK1 cDNAs were used as previously described (10) .
Lymphocyte preparation and culture Peripheral lymph nodes were taken from 5-to 7-week-old male C57BL/6 mice, red blood cell-depleted and surface Ignegative cell suspensions prepared as previously described (10) . These cells were cultured at 10 4 /ml in DMEM supplemented with 8% FCS, 2 mM glutamine and 50 µM 2-mercaptoethanol (culture medium) at 37°C in a humidified 5% CO 2 incubator in plates coated with 10 µg/ml anti-CD3 and 15 µg/ml anti-LFA-1 mAb together with 600 IU/ml recombinant human IL-2 (Cetus, Emeryville, CA) and 100 U/ml baculovirusexpressed recombinant murine IL-4 (15). At day 5, cells were harvested into medium containing 60 IU/ml murine IL-2 and 1 U/ml IL-4 and incubated for a further 24-48 h. Because this culture system leads to the preferential outgrowth of CD8 ϩ cells (10, 16) , Ͼ95% of cells were CD8 ϩ CD4 -by this stage.
T cell transfection and purification of transfectants by flow cytometry Activated T cells were resuspended at 10 7 cells/ml in RPMI 1640 supplemented with 2 mM glutamine and 20 mM HEPES, pH 7.2, and electroporated with plasmid DNA using a Gene Pulse apparatus (BioRad, Hercules, CA). Pulse conditions were 290 V and 960 µF. Electroporated cells were then cultured with 60 IU/ml murine IL-2 and 1 U/ml IL-4 for 22 h prior to staining with anti-human CD25 mAb and FITCconjugated anti-rat IgG antibodies. hCD25 ϩ cells were purified by flow cytometry using a FACS Vantage (Becton Dickinson, Sunnyvale, CA) as previously described (10) .
Measurement of cytokine production
Purified hCD25 ϩ T cells were cultured at 10 5 cells/ml in culture medium in 96-well microtiter plates with or without 0.1 µg/ml plate-bound anti-CD3 mAb for 8 h before supernatant harvest. IL-3 and GM-CSF were measured by FDC-P1 assay, IFN-γ by WEHI-279 growth inhibition assay and IL-4 by ELISA as previously described (10) . IL-5 was measured by T88M assay (17) and IL-10 by ELISA (18) . Control experiments using cytokine standards diluted into supernatants harvested from unstimulated cell cultures that had been incubated for 8 h either with culture medium or with 50 µM PD98059 (see below) showed no effect of residual PD98059 upon the indicator cell lines used for cytokine bioassays.
MEK inhibitor (PD98059) treatment
For experiments measuring cytokine production, 10 6 T cells/ ml culture medium (see above) were pre-incubated for 45 min at 37°C in 5% CO 2 with the relevant dilutions of PD98059 (New England Biolabs, Beverly, MA) (prepared from a 50 mM DMSO stock stored at -20°C) before culture with 1 µg/ml plate-bound anti-CD3 mAb. For experiments measuring ERK activity, 10 7 cells/ml culture medium were pre-incubated with PD98059 as above.
Measurement of ERK activity
Activated T cells were incubated with 1 µg/ml plate-bound anti-CD3 mAb for 30 min. The reaction was stopped and the cells lysed by addition of 4 volumes of ice-cold 1.25ϫlysis buffer containing 1% Triton X-100, 150 mM NaCl, 50 mM Tris, pH 7.6, 25 mM NaF, 1 mM Na 3 VO 4 , 5 mM EDTA, 10 µg/ml leupeptin and 20 µg/ml p-nitrophenylguanidinobenzoate for 0.5 h on ice. Postnuclear supernatants were obtained by centrifugation for 0.25 h at 13,000 g at 4°C and precleared by incubation with Protein A-Sepharose for 30 min at 4°C. Measurement of ERK2myc kinase activity was performed using MBP as substrate, and kinase reactions were stopped by adding 2ϫLaemmli sample buffer and boiling; 25% of each sample was then run on a 15% SDS-PAGE gel and the gel was Coomassie stained, dried and exposed to X-ray film. The remaining 75% was run on an 8% SDS-PAGE gel, transferred to nitrocellulose and immunoblotted with anti-ERK2-specific antibodies. Immunoblotted proteins were detected by enhanced chemiluminescence.
Proteins were immunoprecipitated using antibodies coupled to Protein A-or Protein G-Sepharose for 2-3 h at 4°C as previously described (10, 19) . ERK1 and ERK2 immunoprecipitates were assayed for kinase activity using 0.5 mg/ml myelin basic protein (MBP; Sigma, St Louis, MO) as substrate as previously described (10) . JNK2 immunoprecipitates were assayed for kinase activity using 0.5 mg/ml glutathionine-Stransferase-c-jun (1-79; provided by Professor J. Hancock, Department of Pathology, University of Queensland) as substrate, under conditions identical to those used for ERK assays. Each immunoprecipitate was checked for the relative amount of kinase present by immunoblotting using enhanced chemiluminescence detection as previously described (10, 19) .
Results
We have previously shown that ERK activation acted synergistically with calcium-dependent signaling to induce the production of a number of T cell-derived cytokines by newly activated normal T cells (10) . However, that study did not address the extent to which full ERK activation was required for TCR-stimulated cytokine production. Expression of catalytically inactive MEK1 (CI-MEK1) has been used in a number of studies to block MEK/ERK signaling (12, (20) (21) (22) . We therefore used this approach to investigate the dependence of TCR-stimulated cytokine production on ERK activation. Preliminary experiments revealed that under anti-CD3 mAb stimulation conditions that induced strong ERK activation (stimulation with 1 µg/ml plate-bound anti-CD3ε mAb for 30 min), expression of CI-MEK1 neither reproducibly nor significantly inhibited ERK activation (data not shown). Only under suboptimal anti-CD3 mAb stimulation conditions (0.1 µg/ml plate-bound anti-CD3ε mAb) did we observe significant inhibition of ERK activation. Figure 1 presents data obtained from an experiment involving co-transfection of either CI-MEK1 or empty vector with ERK2myc and measurement of ERK2myc kinase activity in response to anti-CD3 mAb treatment. The anti-CD3 stimulus in this case (0.1 µg/ml platebound anti-CD3 mAb) resulted in weak ERK activation (~2-fold compared to 8-to 10-fold with 1 µg/ml anti-CD3 mAb; see Fig. 3A ) and this activation was blocked by expression of CI-MEK1. This partial inhibitory effect of CI-MEK1 was similar to that observed in other studies where even 10-fold overexpression of CI-MEK1 in transgenic mice failed to block TCR-stimulated ERK activation completely (21, 22) . Consistent with these results, we also found that CI-MEK1 significantly inhibited cytokine production only under suboptimal anti-CD3 mAb stimulation conditions (0.1 µg/ml plate-bound anti-CD3 mAb) (Fig. 2) . This inhibition was most marked with respect to production of IFN-γ (P Ͻ 0.025 by one-sided Student's t-test) and GM-CSF (P Ͻ 0.05) but was not significant in the case of IL-3 (P Ͼ 0.05). Thus expression of CI-MEK1 measurably diminished TCR-stimulated ERK activation and the production of IFN-γ and GM-CSF, but not IL-3, under suboptimal TCR stimulation conditions.
A specific pharmacologic inhibitor of both MEK1 and MEK2, PD98059, has recently been described that provides an alternative means of blocking MEK/ERK signaling (13, 14, 23) . This inhibitor specifically binds inactive MEK1 and MEK2, and prevents activation of these enzymes by upstream MAP kinase kinase kinases such as c-raf in response to stimuli such as nerve growth factor and epidermal growth factor. The exquisite specificity of this inhibitor has been well established and continues to be upheld as new MAP kinase members are characterized (13, 14, 23, 24) . We therefore tested whether PD98059 could block ERK activation in T cells. T cells were pretreated with no inhibitor or with 5 or 50 µM PD98059, then stimulated with 1 µg/ml anti-CD3 mAb, and resultant ERK2 kinase activity was measured. The activity of the related MAP kinase JNK2, which should not be affected by PD98059 (14) , was measured as a control. Figure 3(A) shows an example of one of these experiments and demonstrates a significant dose-dependent decrease in anti-CD3 mAb-stimulated ERK activation in response to PD98059 treatment, that was not evident for JNK2. We also performed a more extensive series of experiments using a 100-fold doserange of PD98059. The combined data from all such experiments are summarized in Fig. 3(B) . At 100 µM PD98059, 80% of the normal anti-CD3 mAb-stimulated increase in ERK1 and ERK2 activity was abolished (the insolubility of PD98059 precluded its use at concentrations Ͼ100 µM). Thus the MEK inhibitor significantly reduced the ability of anti-CD3 mAb treatment to stimulate ERK activity above the baseline and therefore appeared to be a useful tool for studying the requirement for full ERK activation in T cell cytokine production under conditions of strong anti-CD3 mAb stimulation.
The production of IL-3, IL-4, IL-5, IL-10, GM-CSF and IFN-γ was measured in response to anti-CD3 mAb treatment in the presence of varying levels of MEK/ERK inhibition by PD98059. As shown in Fig. 4(A) , production of all six cytokines was reduced in a dose-dependent fashion over a similar dose range. Routine monitoring of each culture for cell viability verified that these effects were not due to MEK inhibitor toxicity. Although ERK activation was still declining at the two highest concentrations of PD98059 (31.5 and 100 µM) (Fig.  3B) , production of IFN-γ, GM-CSF, IL-3 and IL-4 reached plateau levels of inhibition at these doses, and in no case was production completely inhibited (Fig. 4A) . IL-4 production in particular was only reduced by an average of 43% at the inhibition plateau. This residual cytokine production was anti-CD3 mAb stimulation dependent; any measurable constitutive cytokine production was routinely Ͻ1% of that observed in response to anti-CD3 mAb stimulation (data not shown). Thus a component of the anti-CD3 mAb-stimulated production of each of these cytokines was resistant to the effects of ERK inhibition and would not have been further reduced even had total ERK inhibition been achieved. On the other hand, production of IL-5 and IL-10 did not reach plateau levels of inhibition, and it remains possible that, had total inhibition of ERK activation been achieved, this would have completely abolished production of these cytokines. The percent residual cytokine titer at maximum MEK inhibitor concentrations provided a quantitative means to evaluate the contribution of the ERK pathway to production of each cytokine. By one-tailed Student's t-test at 95% confidence levels, significant differences were observed between some of the cytokines, with the following ranking of sensitivity to MEK inhibition: IL-5 ϭ IL-10 Ͼ GM-CSF ϭ IFN-γ Ͼ IL-3 ϭ IL-4.
Concentrations of PD98059 up to 100 µM affected neither anti-CD3 mAb-stimulated cellular phosphotyrosine levels Fig. 4 . PD98059 inhibits cytokine production in response to anti-CD3 mAb but not ionomycin stimulation. (A) T cells were pretreated with medium or with the indicated concentrations of PD98059 for 45 min then stimulated for 8 h with 1 µg/ml plate-bound anti-CD3 mAb before harvesting supernatants for cytokine assays. Data are expressed as the mean and SD of the percentage of anti-CD3 mAb-stimulated cytokine production by cells that received no inhibitor treatment. The IL-3, IL-4, IFN-γ and GM-CSF data were obtained from five separate measurements; the IL-5 and IL-10 data were obtained from three separate measurements. Mean titers in the absence of PD98059 were: IFN-γ, 1744 U/ml; GM-CSF, 6950 pg/ml; IL-3, 22625 pg/ml; IL-4, 7 U/ml; IL-5, 43 U/ml; IL-10, 229 pg/ml. (B) T cells pretreated with either medium or 50 µM PD98059 were incubated with 0.5 µg/ml ionomycin for 8 h before harvesting supernatants for cytokine assays. The data represent individual cytokine titers from three separate experiments performed in parallel with three of the experiments in (A), together with data from an additional two separate experiments measuring IL-3 and GM-CSF production. Mean ionomycin-stimulated titers were: IFN-γ: 70 U/ml with medium, 95 U/ml with PD98059; IL-3: 3877 pg/ml with medium, 5096 pg/ml with PD98059; GM-CSF: 249 pg/ml with medium, 209 pg/ml with PD98059. The threshold of detection of each cytokine is indicated by a horizontal line.
(data not shown) nor activation of the MAP kinase JNK2 (Fig. 3A) . Although these biochemical assays confirmed that PD98059 did not act as a general inhibitor of TCR signaling, such controls did not exclude the possibility that PD98059 might non-specifically inhibit T cell cytokine production. Ionomycin stimulates calcium-dependent signaling events that act independently of ERK activation in eliciting T cell cytokine production (5,6,10; unpublished observations) and therefore should not be affected by PD98059 treatment. As shown in Fig. 4(B) , PD98059 at 50 µM had no reproducible effect on ionomycin-stimulated production of IL-3, GM-CSF or IFN-γ. Thus, the observed effects of PD98059 on anti-CD3 mAbstimulated cytokine production were not due to general impairment of the cells' ability to synthesize cytokines.
Discussion
We have shown that inhibition of TCR-stimulated ERK activation severely diminished the ability of T cells to produce a number of cytokines, leading us to conclude that the ERK pathway is necessary for maximal TCR-stimulated cytokine production. However, the six cytokines we have measured differed quantitatively in their dependence on this pathway. Our collective data (10 and this study) indicate that production of IL-4 is the least responsive to, and has the least requirement for, ERK activation of all the cytokines measured.
An important feature of our studies is that the effects of MEK inhibition and activation were quantitatively different for each of the cytokines measured. Both methods of inhibiting ERK activation that were employed in our study exerted comparable effects upon the production of IFN-γ and GM-CSF, but were less effective in inhibiting IL-3 production. The relative sensitivities of these cytokines to ERK inhibition (IFN-γ ϭ GM-CSF Ͼ IL-3) were different from their responsiveness to constitutive ERK activation (IL-3 Ͼ GM-CSF Ͼ IFN-γ; 10), but we must point out that the effect of constitutive ERK activation was revealed via its synergy with calcium-dependent signaling, in the absence of other signaling pathways elicited by TCR stimulation. The preferential responsiveness of IL-3 production to ERK activation and ionomycin treatment was therefore specific to that particular combination of stimuli, whereas inhibition of ERK activation revealed the requirement for this pathway in the production of each cytokine in response to TCR signaling.
In contrast, we have consistently found that the production of IL-4 is relatively insensitive both to ERK activation in the presence of ionomycin (10) and to ERK inhibition (this study). Thus, although similar proportions of IL-3 and IL-4 production were sensitive to ERK inhibition, we have shown that ERK activation and calcium signaling synergized more effectively to stimulate IL-3 production than to stimulate IL-4 production (10). It appears, therefore, that the signaling pathways which synergize with the ERK pathway to stimulate IL-3 production are different from those that act with the ERK pathway in stimulating IL-4 production, at least with respect to calcium dependence. This constitutes a point of distinction between the ERK-dependent components of IL-3 and IL-4 production.
A significantly higher proportion of IL-4 production was ERK-independent compared to IFN-γ, GM-CSF, and the other type 2 cytokines IL-5 and IL-10. The ERK-dependent components of IL-4, IL-5 and IL-10 production nevertheless showed comparable sensitivity to PD98059 treatment, with 50% inhibition at~10-20 µM. It is therefore possible that these three type 2 cytokines are regulated in part by a shared group of factors with a similar requirement for activation of the ERK pathway, but that they differ in the proportion of production that is ERK dependent. The substantial ERKindependent component of IL-4 production may reflect the control of IL-4 expression by transcription factors, such as c-maf and NIP45 acting together with NF-AT, that are not involved in the transcription of other cytokine genes such as IL-5 (25) . IL-4 transcription might therefore be regulated by a unique combination of factors, the activities of some of which do not require upstream ERK activation.
We expect that the quantitative differences we have observed between cytokines reflect qualitative differences in the way the ERK pathway interacts with other signaling pathways to activate cytokine gene transcription. We had originally proposed that the minimal effect of ERK activation upon IL-4 production, compared to IL-3 and GM-CSF production, could be explained by c-fos/AP-1 induction being the key mediator of ERK activation. The well-documented ability of the ERK to induce c-fos transcription through phosphorylation of elk-1 (reviewed in 26), the ability of AP-1 to act cooperatively with NF-AT in stimulating cytokine gene transcription (3-6), and reports that c-fos was a component of NF-AT/AP-1 complexes that bound the IL-3 and GM-CSF promoters (27, 28) but not the IL-4 promoter (29) supported this proposal. However, it has since been demonstrated in Jurkat T cells that ERK activation was neither necessary nor sufficient for stimulation of AP-1 reporter activity; Rac-1 was both necessary and sufficient for AP-1 induction (5). Instead, the ERK pathway appeared to act upon either NF-AT itself or NF-AT and AP-1-containing complexes at the IL-2 promoter. Additionally, other recent data have shown that the ERK pathway acts via the RSK family of serine/threonine kinases to regulate transcription factors other than elk-1 and c-fos: activation of the Ras/MEK/ERK pathway can lead to NF-κB activation, in part through p90 rsk phosphorylation of IκB-α (30), while the RSK2 isoform can act as a cAMP responsive binding factor (CREB) kinase by phosphorylating the CREB at the activating Ser133 residue (31) . Although there is as yet no evidence that the ERK regulate NF-κB or CREB in T cells, a simple linear cascade linking ERK activation with c-fos and AP-1 induction is unlikely to explain how the ERK pathway regulates cytokine production in T cells. It is more likely that in activated T cells, the ERK pathway acts through a number of downstream mediators, as well as via regulation of NF-AT/ AP-1 complexes (as demonstrated in the case of the IL-2 promoter). The differential effect of ERK inhibition and activation upon the production of each cytokine measured in our studies would reflect the different requirements of each individual cytokine gene promoter for the various transcription factor complexes that are regulated by the ERK pathway.
In summary, we have shown that the MEK/ERK signaling pathway is crucial to normal TCR-stimulated cytokine production and that there is significant variation between cytokines in their dependence upon ERK activation. In light of these results, we expect there to be differences in the way ERKdependent pathways integrate with other signaling pathways to regulate the transcription of each cytokine gene. Identification of the transcription factors in T cells that lie downstream of the ERK and their roles in the transcription of each cytokine gene will be required to understand fully how this pathway integrates with others to regulate inducible cytokine gene expression.
